The $110M raise at a 1.5% discount to market is highly dilutive (~25% of current market cap) and signals the company needed capital to fund operations given its pre-revenue status. Monitor for the resale registration filing within 45 days, which could enable further distribution by investors. The presence of multiple healthcare-focused funds suggests potential for near-term price support, but the dilutive overhang is significant.
Price Chart
Executive Summary
Climb Bio entered into a securities purchase agreement for a $110.0 million private placement, selling 9,481,000 shares at $9.50/share and 2,106,000 pre-funded warrants at $9.4999/warrant to institutional investors including RA Capital, Adage Capital, and others. The offering represents approximately 25% dilution based on the current $454M market cap and is priced at a 1.5% discount to the last trade. Proceeds extend the cash runway for late-stage development of budoprutug and CLYM116, but the dilutive financing signals the company needed capital to fund operations.
Key Financial Metrics
Key Facts
- Aggregate gross proceeds of approximately $110.0 million from a private placement of 9,481,000 shares at $9.50/share and 2,106,000 pre-funded warrants at $9.4999/warrant
- Pre-funded warrants have an exercise price of $0.0001 per share, exercisable immediately until exercised in full
- Offering priced at $9.50 per share vs. current market cap of $454M — approximately 25% dilution
- Closing expected on or about April 29, 2026, subject to customary conditions
- Placement agents include Leerink Partners, Piper Sandler, Raymond James, BTIG, Baird, and H.C. Wainwright
- Company must file a resale registration statement within 45 days of closing, with liquidated damages of 1.0% per 30-day period for delays (capped at 5.0% of purchase price)
- RA Capital's pre-funded warrants include a 33.0% beneficial ownership limitation and remain subject to the existing Exchange Agreement requiring proportional voting for shares above 33.0%
- Cash runway extended to support late-stage development of budoprutug (anti-CD19) and CLYM116 (anti-APRIL)
Financial Impact
Approximately $110.0 million gross proceeds, representing ~25% dilution on a $454M market cap. Net proceeds after placement agent fees and expenses will be lower.
Risk Factors
- Approximately 25% dilution from the offering may pressure the stock price
- Registration rights agreement allows investors to resell shares, potentially creating overhang
- Pre-funded warrants are immediately exercisable, adding further potential dilution
- Company is pre-revenue with no approved products; cash burn continues
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-183711 |
| Document: d153155dex102.htm | 0001193125-26-183711 |
| Document: d153155dex41.htm | 0001193125-26-183711 |
| Document: d153155d8k.htm | 0001193125-26-183711 |
| Document: d153155dex991.htm | 0001193125-26-183711 |
| Document: 0001193125-26-183711-index-headers.html | 0001193125-26-183711 |
| Document: 0001193125-26-183711-index.html | 0001193125-26-183711 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 8-K | $10.92 | awaiting T+1 | — | $8.81 (−19.32%) |
Oct 23, 2026 3d ago | 8-K | $10.47 | awaiting T+1 | — | $8.81 (−15.85%) |
Oct 23, 2026 3d ago | Press Release | $10.34 | awaiting T+1 | — | $8.81 (−14.80%) |
Sep 22, 2026 4w ago | Institutional Cluster | $14.21 $12.52 | ▼ −11.89% | ▼ −11.17% | $8.81 (−38.00%) |
Sep 3, 2026 7w ago | 8-K | $14.59 $15.52 | ▲ +6.37% | ▲ +6.76% | $8.81 (−39.62%) |
Aug 14, 2026 10w ago | 8-K | $16.33 $17.44 | ▲ +6.80% | ▲ +7.27% | $8.81 (−46.05%) |
Aug 6, 2026 11w ago | 8-K | $14.00 $14.00 | · 0.00% | ▼ −0.61% | $8.81 (−37.07%) |
Jun 30, 2026 16w ago | 144 | $13.29 $12.90 | ▼ −2.93% | ▼ −2.80% | $8.81 (−33.71%) |
Jun 12, 2026 19w ago | 8-K | $11.49 $10.71 | ▲ +6.79% | ▲ +6.19% | $8.81 (+23.32%) |
Jun 12, 2026 19w ago | 424B5 | $11.49 $10.71 | ▲ +6.79% | ▲ +6.19% | $8.81 (+23.32%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers